Rare genetic variation in VE-PTP is associated with central serous chorioretinopathy, venous dysfunction and glaucoma

Competing Interest Statement

Dr. Rossin and Dr. Ramo are named inventors on a provisional patent application that describes the secondary use of intravitreal Anti-Ang2 medications for use in the treatment of central serous chorioretinopathy. Dr. Ellinor receives sponsored research support from Bayer AG, IBM Research, Bristol Myers Squibb, Pfizer and Novo Nordisk; he has also served on advisory boards or consulted for MyoKardia and Bayer AG. The remaining authors declare no competing interests.

Funding Statement

E.J.R. is supported by K12EY016335 from the National Institutes of Health. We acknowledge NIH Core Grants to the Departments of Ophthalmology at Case Western Reserve University (P30EY011373) and Cleveland Clinic School of Medicine at Case Western Reserve University (P30EY025585) and unrestricted support from Research to Prevent Blindness to the Departments of Ophthalmology at Case Western Reserve University, Cleveland Clinic School of Medicine at Case Western Reserve University, and SUNY-Buffalo. S.K.I. was supported by the International Retinal Research Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Study subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts were collected between the Finnish Biobank Act coming into effect (in September 2013) and the start of FinnGen (August 2017). The MVP024 study protocol was approved by the Veterans Affairs (VA) central Institutional Review Board (IRB). MVP participants provided written informed consent. Use of All of Us data was approved under a data use agreement between the Massachusetts General Hospital and the All of Us research program. Study participants provided written informed consent.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes